CommentaryAssociation of oncolytic adenoviruses with chemotherapies: An overview and future directions
Graphical abstract
Section snippets
Organization of adenovirus genome
Adenoviruses constitute a large family of non-enveloped DNA virus that infect different hosts from fish to mammals. Among these viruses, human Ad serotype 5 is the best characterized in term of pathogenesis, molecular biology and protein functions. Ad entry into a target cell is followed by viral gene transcription. The first region to be transcribed, E1, is divided into E1A and E1B sub-regions [2]. E1A encodes 13S, 12S, 11S, 10S and 9S mRNA, leading to the production of 289R, 243R, 217R, 171R
Principles
Chemotherapeutic drugs are widely used to treat cancers and constitute powerful weapons against tumor development [17], [18]. These compounds are classified into two different families corresponding to standard chemotherapeutic drugs and molecular-targeted drugs [17], [18]. The first family includes mitotic inhibitors, antibiotics, anti-metabolites, platine salts, alkylating agents, and topoisomerase inhibitors. Drugs from this family interact with DNA to form covalent links with DNA strands to
Future directions
As discussed in the previous paragraphs, many studies have investigated the potential of CRAd–chemotherapeutic drug combination. Among classical chemotherapeutic drugs, those belonging to the mitotic inhibitor (paclitaxel, docetaxel), antibiotic (doxorubicin), and topoisomerase inhibitor (mitoxantrone) families showed a synergistic or additive response with CRAd (Table 1). Among targeted chemotherapeutic drugs, mTOR inhibitors as well as HDACi were able to act in synergy with CRAd to inhibit
Conflict of interest
The authors have no competing financial interests to declare.
References (73)
- et al.
Current issues and future directions of oncolytic adenoviruses
Mol Ther
(2010) - et al.
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
Cancer Cell
(2004) - et al.
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy
Mol Ther
(2003) - et al.
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
Mol Ther
(2006) - et al.
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
Mol Ther
(2010) - et al.
Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus
Mol Ther
(2006) - et al.
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
Mol Ther
(2011) - et al.
Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death
Mol Ther
(2008) - et al.
Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures
Eur J Cancer
(2010) - et al.
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
Exp Cell Res
(2006)
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy
Mol Ther
Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses
Mol Ther
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer
Mol Ther
Inhibition of the inflammatory cytokine TNF-alpha increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression
Mol Ther
Oncolytic virotherapy
Nat Biotechnol
p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing
Oncogene
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Curr Gene Ther
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Nat Med
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Oncogene
Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors
Methods Mol Med
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
Clin Cancer Res
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
J Clin Oncol
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer
J Clin Oncol
Systemic delivery of oncolytic viruses: hopes and hurdles
Adv Virol
Timeline chemotherapy and the war on cancer
Nat Rev Cancer
A history of cancer chemotherapy
Cancer Res
Microtubules as a target for anticancer drugs
Nat Rev Cancer
ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
Cancer Res
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel
Cancer Res
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy
Int J Cancer
Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer
Oncogene
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region
PLoS ONE
Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells
Int J Mol Sci
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
Pharmacol Rev
A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin
Cancer Res
Cited by (31)
Enhanced oncolytic activity of E4orf6-deficient adenovirus by facilitating nuclear export of HuR
2020, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Conditionally replicative adenovirus (CRAd) is an attractive anticancer tool due to its cell-specific propagation and subsequent release of a large number of progeny viruses capable of selectively infecting surrounding cancer cells [1]. Furthermore, in combination with gene therapy, radiotherapy, or chemotherapeutic drugs, oncolytic adenoviruses tend to have a more potent antitumor effect [2]. The early gene products of adenoviruses like E1B55k and E4orf6 retain the modulatory functions of viral and host cell mRNA [3,4].
Virotherapy: From single agents to combinatorial treatments
2020, Biochemical PharmacologyCitation Excerpt :Due to the relevance of taxanes in cancer therapy, several groups have exploited their effects to enhance the therapeutic efficacy of OVs. A synergistic cytotoxic effect and/or a significant antitumour effect were observed using oncolytic adenoviruses and taxanes [27]. The mechanism of action of oncolytic adenoviruse and paclitaxel combination was investigated.
Polymeric oncolytic adenovirus for cancer gene therapy
2015, Journal of Controlled ReleaseCitation Excerpt :See Tables 3 and 4. In recent clinical trials, combined oncolytic Ad and chemotherapy could convey stronger anti-tumor effects by providing synergistic effects by oncolysis and chemotherapeutic mechanism, potentially attenuating cancer cell resistance to virotherapy or chemotherapy [37,38]. Deeper understanding of complex interactions and molecular mechanisms between the oncolytic Ad, adjuvant chemotherapy or radiation therapy, and tumor must be followed the pros and cons of cancer therapeutics.
Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells
2015, Biochemical and Biophysical Research CommunicationsCitation Excerpt :This work demonstrates the feasibility of specific killing of HPV-positive tumor cells in vitro and in vivo by the use of adenoviruses expressing anti-E6 miRNA. The efficiency in vivo could be improved by transferring the miRNA expression cassettes into conditionally replicative adenoviruses (CRAd) which should allow a better killing of tumor cells and an improved vector dissemination [20]. Another possibility would be the use of a combinatorial treatment with Ad18_2 and Cisplatin [8].
Exploring nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders
2023, Turkish Journal of Biochemistry